In exercise of powers conferred by Section 3 of the Foreign Trade Development Regulation Act,

## Policy Analysis Report: Amendment to Export Policy of Injection Remdesivir and Remdesivir API **1. Executive Summary:** This report analyzes an amendment to the export policy regarding Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API). Based on the provided notification, the amendment revises the export policy by changing the export category of Remdesivir and Remdesivir API from "Prohibited" to "Restricted" and clarifies the export procedure related to Advance Authorizations. This report details these changes, their likely rationale, and the expected impact on stakeholders. **2. Introduction:** This report aims to provide a detailed analysis of the notification amending the export policy of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API), based solely on the information provided in the official government text. **3. Policy Overview:** * **Original Policy Amended:** This notification amends Notification No. 01/2015-20 dated 11.04.2021, related to the export of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API). * **Core Objective(s):** Based on the text, the objective appears to be to adjust the export restrictions on Remdesivir products, potentially to balance domestic needs with export opportunities while ensuring proper regulation of the export process. **4. Background and Rationale:** The original policy likely prohibited the export of Remdesivir to ensure sufficient domestic supply during a period of high demand, possibly related to a health crisis. This amendment likely reflects a change in circumstances, such as increased domestic production capacity or a decline in domestic demand, allowing for a controlled resumption of exports. The need for the amendment may be to allow for exports under specific controlled circumstances, as the policy moves from a complete prohibition to a restricted category. **5. Key Provisions / Changes:** This is an amendment to an existing policy. The key changes introduced by this notification are: * **Specific Part of the Original Policy Changed:** The amendment directly alters the export policy status of "Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients API" with specific HS codes. * **New Rule/Provision:** The export policy for Injection Remdesivir and Remdesivir API falling under Ex 293499 207AA and Ex 300490 has been changed from "Prohibited" to "Restricted." Additionally, the export of Remdesivir Injections/API against Advance Authorizations issued under Chapter 4 of FTP/HBP shall not require a separate export authorization or permission. * **Difference/Effect of the Change:** The shift from "Prohibited" to "Restricted" allows for exports under certain conditions, which will be defined by the "Restricted" category's requirements. The clarification regarding Advance Authorizations streamlines the export process for those operating under that framework, removing the need for additional approvals. **6. Target Audience and Stakeholders:** The primary target audience and stakeholders directly affected by these changes are: * Pharmaceutical manufacturers and exporters of Remdesivir and Remdesivir API. * Entities utilizing Advance Authorizations for the export of these products. * Customs officials involved in regulating and processing exports. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The Directorate General of Foreign Trade (DGFT) under the Ministry of Commerce and Industry is responsible for implementing and overseeing this amended policy. * **Timelines/Procedures:** The amendment takes effect "with immediate effect," implying immediate implementation. The specific procedures for exporting Remdesivir under the "Restricted" category are not detailed in this notification and would likely be outlined in separate guidelines or regulations issued by the DGFT. * **Amendment-Specific Implementation:** The altered status of Remdesivir exports will need to be implemented by customs officials immediately, while exporters should find the new regulations regarding Advance Authorizations relatively straightforward to implement. **8. Expected Outcomes / Impact of Changes:** The likely intended outcomes of these changes are: * **Increased Export Opportunities:** The shift to a "Restricted" category allows for controlled exports of Remdesivir, potentially boosting revenue for manufacturers while adhering to regulatory oversight. * **Streamlined Export Process:** The clarification regarding Advance Authorizations reduces bureaucratic hurdles for exporters utilizing this mechanism, potentially accelerating export procedures. * **Controlled Supply:** The "Restricted" category suggests that the government aims to balance export opportunities with the need to maintain an adequate domestic supply of Remdesivir. **9. Conclusion:** This notification amends the export policy for Injection Remdesivir and Remdesivir API, changing its status from "Prohibited" to "Restricted" and streamlining the process for exports under Advance Authorizations. The amendment likely reflects a shift in the domestic supply situation, aiming to balance export opportunities with the need to maintain an adequate domestic supply. Stakeholders, particularly pharmaceutical manufacturers and exporters, should carefully review any subsequent guidelines or regulations issued by the DGFT to ensure compliance with the new "Restricted" export policy.

Key Entities Referenced